Phaseline

Companies › BicycleTx

BicycleTx: clinical trials, targets and expected readouts

4 active drug programs in 7 registered trials: 4 Phase 2, 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
nuzefatide pevedotin (BT5528)
EphA2-targeting antibody-drug conjugate
EPHA2Phase 2Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumor Historically Known for High EphA2 ExpressionDec 2026
Zelenectide pevedotin
anti-NECTIN4 antibody-drug conjugate
NECTIN4Phase 2Metastatic Urothelial Cancer; Breast Cancer; Non-Small Cell Lung CancerMar 2028
BT7480
Bicyclic peptide targeting Nectin-4
NECTIN4Phase 1Advanced Solid TumorDec 2026
BT8009
Bicyclic Toxin Conjugate (BTC) targeting Nectin-4-expressing malignancies
NECTIN4Phase 1Urinary Bladder NeoplasmJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05163041BT7480Phase 1Advanced Solid TumorOncologyDec 2026
NCT04180371nuzefatide pevedotin (BT5528)Phase 1Advanced Solid Tumor Historically Known for High EphA2 ExpressionOncologyDec 2026
NCT04561362BT8009Phase 1Urinary Bladder NeoplasmOncologyJan 2027
NCT06225596Zelenectide pevedotinPhase 2Metastatic Urothelial CancerOncologyMar 2028
NCT06840483Zelenectide pevedotinPhase 2Breast CancerOncologyJun 2028
NCT06933329Zelenectide pevedotinPhase 2Non-Small Cell Lung CancerOncologyAug 2028
NCT07450859nuzefatide pevedotin (BT5528)Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)OncologyMar 2029

From the company's SEC filings

Cash of $470m on 2026-09-30; operating cash outflow about $209m a year; runway about 27 months at that burn, to Dec 2028; 3 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

NECTIN4 (3) EPHA2 (1)

Companies with the same targets

Tianjin ConjuStar Biologics Mabwell (Shanghai) Bioscience Aktis Oncology Regeneron Pharmaceuticals Innate Pharma Astellas Samsung Bioepis Beijing Biotech Akeso Context Therapeutics

Companies built like this

Tianjin ConjuStar Biologics Revolution Medicines IDEAYA Biosciences Replimune HRYZ Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.